156 related articles for article (PubMed ID: 33035615)
1. A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis.
Grillo E; Corsini M; Ravelli C; di Somma M; Zammataro L; Monti E; Presta M; Mitola S
Cancer Lett; 2021 Jan; 496():84-92. PubMed ID: 33035615
[TBL] [Abstract][Full Text] [Related]
2. Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence.
Grillo E; Corsini M; Ravelli C; Zammataro L; Bacci M; Morandi A; Monti E; Presta M; Mitola S
Cancer Lett; 2021 Jun; 507():80-88. PubMed ID: 33744390
[TBL] [Abstract][Full Text] [Related]
3. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
4. ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition.
Guo W; Ma J; Yang Y; Guo S; Zhang W; Zhao T; Yi X; Wang H; Wang S; Liu Y; Dai W; Chen X; Shi Q; Wang G; Gao T; Li C
Clin Cancer Res; 2020 Jun; 26(11):2725-2739. PubMed ID: 32034077
[TBL] [Abstract][Full Text] [Related]
5. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
[TBL] [Abstract][Full Text] [Related]
6. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
7. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
[TBL] [Abstract][Full Text] [Related]
8. SUMOylation of vascular endothelial growth factor receptor 2 inhibits the proliferation, migration, and angiogenesis signaling pathway in non-small cell lung cancer.
Wang M; Jiang X
Anticancer Drugs; 2020 Jun; 31(5):492-499. PubMed ID: 31922962
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA LINC00520 promotes the proliferation and metastasis of malignant melanoma by inducing the miR-125b-5p/EIF5A2 axis.
Luan W; Ding Y; Yuan H; Ma S; Ruan H; Wang J; Lu F; Bu X
J Exp Clin Cancer Res; 2020 May; 39(1):96. PubMed ID: 32466797
[TBL] [Abstract][Full Text] [Related]
10. STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation.
Granado-Martínez P; Garcia-Ortega S; González-Sánchez E; McGrail K; Selgas R; Grueso J; Gil R; Naldaiz-Gastesi N; Rhodes AC; Hernandez-Losa J; Ferrer B; Canals F; Villanueva J; Méndez O; Espinosa-Gil S; Lizcano JM; Muñoz-Couselo E; García-Patos V; Recio JA
Commun Biol; 2020 Jul; 3(1):366. PubMed ID: 32647375
[TBL] [Abstract][Full Text] [Related]
11. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.
Qiu H; Li J; Liu Q; Tang M; Wang Y
Cell Cycle; 2018; 17(10):1235-1244. PubMed ID: 29886786
[TBL] [Abstract][Full Text] [Related]
12. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
13. VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer.
Lian L; Li XL; Xu MD; Li XM; Wu MY; Zhang Y; Tao M; Li W; Shen XM; Zhou C; Jiang M
BMC Cancer; 2019 Feb; 19(1):183. PubMed ID: 30819137
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
15. Isoprenaline/β2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis.
Lu Y; Xu Q; Zuo Y; Liu L; Liu S; Chen L; Wang K; Lei Y; Zhao X; Li Y
BMC Cancer; 2017 Dec; 17(1):875. PubMed ID: 29262812
[TBL] [Abstract][Full Text] [Related]
16. Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
Toledo RA; Garralda E; Mitsi M; Pons T; Monsech J; Vega E; Otero Á; Albarran MI; Baños N; Durán Y; Bonilla V; Sarno F; Camacho-Artacho M; Sanchez-Perez T; Perea S; Álvarez R; De Martino A; Lietha D; Blanco-Aparicio C; Cubillo A; Domínguez O; Martínez-Torrecuadrada JL; Hidalgo M
Clin Cancer Res; 2018 Aug; 24(15):3550-3559. PubMed ID: 29588308
[No Abstract] [Full Text] [Related]
17. Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway.
Liu J; Qu L; Meng L; Shou C
J Exp Clin Cancer Res; 2019 Aug; 38(1):370. PubMed ID: 31438997
[TBL] [Abstract][Full Text] [Related]
18. Cystathionine‑γ‑lyase promotes the metastasis of breast cancer via the VEGF signaling pathway.
Wang L; Shi H; Liu Y; Zhang W; Duan X; Li M; Shi X; Wang T
Int J Oncol; 2019 Aug; 55(2):473-487. PubMed ID: 31173185
[TBL] [Abstract][Full Text] [Related]
19. Disruption of the EGFR-SQSTM1 interaction by a stapled peptide suppresses lung cancer via activating autophagy and inhibiting EGFR signaling.
Yu JJ; Zhou DD; Cui B; Zhang C; Tan FW; Chang S; Li K; Lv XX; Zhang XW; Shang S; Xiang YJ; Chen F; Yu JM; Liu SS; Wang F; Hu ZW; Hua F
Cancer Lett; 2020 Apr; 474():23-35. PubMed ID: 31931029
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models.
Li Q; Kim YS; An JH; Kwon JA; Han SH; Song WJ; Youn HY
BMC Vet Res; 2021 Oct; 17(1):338. PubMed ID: 34702279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
